Home Analysts Viewpoint Taking a Closer Look At Puma Biotechnology Inc. (PBYI) Following Its Recent Trade

Taking a Closer Look At Puma Biotechnology Inc. (PBYI) Following Its Recent Trade

0
Taking a Closer Look At Puma Biotechnology Inc. (PBYI) Following Its Recent Trade
PFE Stock

Puma Biotechnology Inc.’s recently made public that its insider HUNT DOUGLAS M unloaded Company’s shares for reported $965.0 on Nov 02. In the deal valued at $2.25 per share,429 shares were sold. As a result of this transaction, HUNT DOUGLAS M now holds 76,004 shares worth roughly $ 0.24 million.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


Then, AUERBACH ALAN H sold 1,242 shares, generating $2,794 in total proceeds. Upon selling the shares at $2.25, the President and CEO now owns 6,312,949 shares.

Before that, NOUGUES MAXIMO F sold 163 shares. Puma Biotechnology Inc. shares valued at $367 were divested by the Chief Financial Officer at a price of $2.25 per share. As a result of the transaction, NOUGUES MAXIMO F now holds 111,085 shares, worth roughly $0.35 million.

Citigroup upgraded its Puma Biotechnology Inc. [PBYI] rating to a Buy from a a Neutral in a research note published on Monday. PT values the company’s stock at a premium of 71.55 to its Monday closing price. Goldman also remained covering PBYI and has decreased its forecast on October 08, 2019 with a “Sell” recommendation from previously “Neutral” rating. Citigroup revised its rating on May 10, 2019. It rated PBYI as “a Neutral” which previously was an “a Buy”.

Price Performance Review of PBYI

On Monday, Puma Biotechnology Inc. [NASDAQ:PBYI] saw its stock jump 15.50% to $3.13. On the same session, the stock had its day’s lowest price of $2.79, but rose to a high of $3.16. Over the last five days, the stock has gained 43.58%. Puma Biotechnology Inc. shares have risen nearly 2.96% since the year began. Nevertheless, the stocks have fallen -21.95% over the past one year. While a 52-week high of $4.95 was reached on 08/08/22, a 52-week low of $1.60 was recorded on 05/12/22. SMA at 50 days reached $2.43, while 200 days put it at $2.62. A total of 0.65 million shares were traded, compared to the trading of 0.12 million shares in the previous session.

Levels Of Support And Resistance For PBYI Stock

The 24-hour chart illustrates a support level at 2.89, which if violated will result in even more drops to 2.66. On the upside, there is a resistance level at 3.26. A further resistance level may holdings at 3.40. The Relative Strength Index (RSI) on the 14-day chart is 73.26, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.35, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 2.78%. Stochastics %K at 71.92% indicates the stock is a holding.

How much short interest is there in Puma Biotechnology Inc.?

A steep rise in short interest was recorded in Puma Biotechnology Inc. stocks on Jul 14, 2022, dropping by -1.59 million shares to a total of 1.86 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 3.45 million shares. There was a decline of -85.48%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 5.06% of the overall stock float, the days-to-cover ratio (short ratio) fell to 3.14.

Puma Biotechnology Inc. [PBYI] – Who Are The Largest Shareholders?

In filings from Camber Capital Management LP, it is revealed that the company now owns 4,235,000 shares, or roughly 9.30% of the outstanding PBYI shares. In other words, the investor’s shares have risen by 235,000 from its previous 13-F filing of 4000000.0. Additionally, The Vanguard Group, Inc. increased 6.35% of its stake after which the total value it holdings stand at $8,572,257, while Millennium Management LLC added 15.95% of its stake to hold $5.25 million in the firm. Over the last quarter, Renaissance Technologies LLC purchased 205,700 shares of Puma Biotechnology Inc., while Acadian Asset Management LLC bought 116,929 shares. At present, Athyrium Capital Management LP is holding 1,792,114 shares valued at $4.25 million. Armistice Capital LLC owned 1,500,000 shares of the company at the time of its most recent 13F filing, worth $3.56 million.

According to FactSet, Puma Biotechnology Inc.’s share price will average $5.40 in the next year, based on opinions of analysts polled by the firm. This is up nearly 84.5 percent from its previous closing price of $2.71. Analysts expect Puma Biotechnology Inc. stock to reach the higher price of $8.00, while the lowest price estimate is $2.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]